Brief: Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults
02/06/2026 21:48
BRIEF-Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults June 2 (Reuters) - Vaxcyte Inc PCVX.O:
VAXCYTE DOSES FIRST PARTICIPANT IN PHASE 1 STUDY EVALUATING VAX-A1 FOR THE PREVENTION OF DISEASE CAUSED BY GROUP A STREPTOCOCCUS IN HEALTHY ADULTS
VAXCYTE - EXPECTS TOPLINE DATA FROM VAX-A1 PHASE 1 STUDY IN H2 2027
Source text: ID:nGNXKmZzl
Further company coverage: PCVX.O
((Reuters.Briefs@thomsonreuters.com;))